Prenetics Global Limited (PRENW) Stock Price & Analysis
Prenetics Global Limited (PRENW) — price $0.0099 (-6.60%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Prenetics Global Limited · PRENW
Prenetics Global Limited is an investment holding company specializing in diagnostics and genetic testing, offering solutions like CircleDNA, Circle HealthPod, and ColoClear. The company focuses on preventative healthcare and early disease detection, operating primarily from its headquarters in Hong Kong.
Price as of Oct 2, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0099 | |
| Change on the day | -6.60% | |
| 52-week range | $0.0106 – $0.022 | |
| Shares traded on the day | 414.4K |
Price & events
Other perspectives
Council score for Prenetics Global (PRENW): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the PRENW film — every key number, told as a short cinematic story
~2 min · open the film
What is Prenetics Global (PRENW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Prenetics Global Limited (PRENW) is the company analyzed here. It employs 98 people and is led by Sheng Wu Yeung. In Q2 FY2026 it reported revenue of $46M and net income of -$9M.
What do the latest results show for Prenetics Global (PRENW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $46M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $46M | -$9M | -$0.52 (diluted) |
| Q1 FY2026 | $36M | -$23M | -$1.36 (diluted) |
| Q4 FY2025 | $37M | -$28M | -$1.75 (diluted) |
| Q3 FY2025 | $24M | -$7M | -$0.53 (diluted) |
What are the financial strengths and risks for Prenetics Global (PRENW)?
Short answer · as of
The distress and quality screens read Altman Z 3.77 · Piotroski F 4. Trailing ratios: ROE -49.2% · ROA -44.0% · current ratio 4.04 · earnings yield -17.1% · free-cash-flow yield -8.8%.
Data-derived red flags
- Negative return on equity (-49.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
What has been published about Prenetics Global (PRENW)?
- Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
- Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
- Prenetics’ IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
- Prenetics Global Limited Q2 2026 Earnings Call Summary
Common Questions About PRENW
These answers are editorial: 1 of these 1 answer is drawn from the PRENW research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What is Prenetics Global Limited's strategy for growth in the preventative healthcare market?
Prenetics Global Limited's growth strategy in the preventative healthcare market is centered on its diverse portfolio of accessible diagnostic and genetic testing solutions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (13 figures)
The 13 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 7 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0099 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T06:34:27.234Z. | |
px.change | Change on the day | -6.60% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.0007 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 414.4K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $46M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$9M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0106 – $0.022 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 98 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | Sheng Wu Yeung | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.77 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-08-20 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -49.2% · ROA -44.0% · current ratio 4.04 · earnings yield -17.1% · free-cash-flow yield -8.8% | UNRECORDED | Stored key metrics — Captured 2026-09-30 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.